Topical Ruxolitinib for Cutaneous Chronic Graft-versus-Host Disease

This trial tests a cream called ruxolitinib (Ruxolitinib Cream) to determine its safety and effectiveness for individuals with chronic cutaneous graft-versus-host disease (GVHD), a condition that can occur after a stem cell transplant. The study compares this cream with regular moisturizers to identify which is more effective for this specific type of GVHD that does not affect deeper skin layers. Individuals who have undergone a stem cell transplant, experience skin issues from GVHD, and can apply creams independently or with assistance may be suitable candidates for this trial. As a Phase 2 trial, the research measures the treatment's effectiveness in an initial, smaller group of participants.

You may need to stop using certain topical treatments like corticosteroids, calcineurin inhibitors, and moisturizers on the first day of the study. However, if you are on systemic therapy for GVHD, it must be stable for the past 4 weeks, but you can continue it during the study.

Research has shown that ruxolitinib cream has been studied for safety in treating skin problems related to graft-versus-host disease (GVHD). The findings suggest it could be a safe option for people with this condition. The FDA has approved the cream, called Opzelura, for other uses, indicating a known safety record. Previous studies found that patients generally handle it well, with only a few cases of mild skin irritation. Overall, the evidence suggests that ruxolitinib cream is a promising and well-tolerated choice for those dealing with non-sclerotic chronic cutaneous GVHD.¹²³⁴⁵

Unlike standard treatments for cutaneous chronic graft-versus-host disease (GVHD), which often include systemic drugs like corticosteroids, Ruxolitinib Cream offers a targeted topical approach. This cream is unique because it specifically delivers ruxolitinib, a Janus kinase (JAK) inhibitor, directly to affected skin areas, potentially reducing systemic side effects. Researchers are excited about this treatment because it targets the inflammatory pathways involved in GVHD, which could provide relief with fewer side effects than oral medications.

Research has shown that ruxolitinib cream, which participants in this trial will receive, can help treat chronic skin problems caused by graft-versus-host disease (cGVHD). In one study, 82% of patients with cGVHD experienced complete or partial symptom improvement with ruxolitinib treatment. Another study found that ruxolitinib cream improved affected skin more effectively than a placebo cream. The cream blocks certain proteins that may cause cGVHD, potentially reducing symptoms without the serious side effects of other treatments. Overall, these findings suggest that ruxolitinib cream could be a promising option for managing cGVHD symptoms.¹⁶⁷⁸⁹